The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Global circulating free DNA methylation and fragmentome deconvolution in patients with metastatic renal cell carcinoma treated with immunotherapy (GOLDEN).
 
Pavlina Spiliopoulou
Honoraria - Pfizer
 
Ming Han
No Relationships to Disclose
 
Brooke Wilson
No Relationships to Disclose
 
Adrian G. Sacher
Research Funding - AstraZeneca; BMS; Genentech/Roche
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Genentech/Roche
 
Nazanin Fallah-Rad
No Relationships to Disclose
 
Srikala S. Sridhar
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Research Funding - Bayer (Inst); Janssen (Inst); Pfizer (Inst)
 
Elizabeth Shah
No Relationships to Disclose
 
Vanessa Speers
No Relationships to Disclose
 
Celeste Yu
No Relationships to Disclose
 
Madhuran Thiagarajah
No Relationships to Disclose
 
Ilinca Lungu
No Relationships to Disclose
 
Sarah Louise Picardo
No Relationships to Disclose
 
Marco Iafolla
Honoraria - Bayer; Ipsen; Merck; Sanofi
Consulting or Advisory Role - Novartis
Research Funding - Bristol-Myers Squib; Novartis; Pfizer
 
Bernard Lam
No Relationships to Disclose
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Amgen; Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Hookipa Pharma; InterRNA; Janpix; Janssen; Merck; Navire; Oncorus; Relay Therapeutics; Roche; Sanofi; Seagen; Tessa Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)
 
Aaron Richard Hansen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Merck; Novartis
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Neoleukin Therapeutics (Inst); Pfizer/EMD Serono (Inst); Roche/Genentech (Inst)